This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Powles, T. J. Search for Related Content PubMed PubMed Citation Articles by Powles, T. J.

Breast Cancer Prevention

Royal Marsden NHS Trust, and Institute of Cancer Research, London, United Kingdom

Correspondence: Trevor J. Powles, M.D., Ph.D., Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, United Kingdom. Telephone: 020-8661-3361; Fax: 020-8770-7313; e-mail: trevor.powles{at}rmh.nthames.nhs.uk

Epidemiological, experimental, and clinical data strongly support the possibility that breast cancer will be prevented by using anti-estrogenic interventions in healthy women. Three trials involving over 20,000 women have so far been reported using tamoxifen 20 mg/day or placebo in healthy women to chemoprevent breast cancer. The American National Surgical Adjuvant Breast and Bowel P-1 Project randomized over 13,000 women to take tamoxifen or placebo and showed a 49% reduction in the early incidence of breast cancer. This was associated with a reduction in osteoporotic fractures but increases in the risks of endometrial cancer, cataract, and thromboembolism. The Royal Marsden tamoxifen trial randomized 2,500 women, and the Italian national trial randomized 5,000 women. Interim analyses from these two trials showed no effect on the early incidence of breast cancer. These results, therefore, have not been able to clearly show an overall clinical benefit of giving tamoxifen to healthy women, nor have they shown which women are likely to benefit.

Another selective anti-estrogen (SERM), raloxifene, has been used in a clinical trial to prevent osteoporotic fractures in women with low bone mineral density. Annual mammography in this trial has shown an approximate 80% reduction in the early incidence of breast cancer, and further follow-up of this trial continues. New trials in chemoprevention of breast cancer being started or being proposed use luteinizing-hormone-releasing hormone analogues, aromatase inhibitors, and other SERMs.

Key Words. Breast cancer • Chemoprevention • Tamoxifen • Raloxifene

This article has been cited by other articles:

				A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]

				R. R. Love Breast Cancer Prevention Oncologist, April 1, 2002; 7(2): 100 - 102. [Full Text] [PDF]

				V. G. Vogel Prevention in the Balance Oncologist, April 1, 2002; 7(2): 103 - 105. [Full Text] [PDF]